The medical technology company’s growing installed base follows 26% U.S. revenue growth in the first half, with future consumable sales dependent on hospital utilization.
Key Investor Takeaways
- Nuwellis (NASDAQ:NUWE) has sold 31 Aquadex SmartFlow consoles year-to-date in 2026, exceeding full-year sales in seven of the previous 10 years.
- Console sales are on pace to rank among the company’s three highest annual totals, according to management.
- U.S. revenue increased 26% year over year during the first half of 2026, supported by growth across three clinical markets.
- Each additional console creates potential recurring revenue from single-use blood circuits.
- The financial impact of the expanding installed base will depend on hospital utilization and subsequent consumable purchases.
Why NUWE Stock Is in Focus
Nuwellis reported continued commercial adoption of its Aquadex SmartFlow system, with 31 consoles sold so far in 2026.
The year-to-date figure has already surpassed annual console sales recorded in seven of the past 10 years, putting the company on track for one of its three highest sales years if the current pace continues.
Nuwellis noted that its previous peak console-placement years included the COVID-19 pandemic, when hospitals expanded access to fluid-removal technologies amid unusually high critical-care demand.
The latest performance is occurring under more typical hospital operating conditions, according to the company.
Aquadex is used to provide controlled ultrafiltration therapy for patients requiring fluid removal. The system consists of a console, catheter and disposable blood circuit.
Nuwellis reported adoption across its core U.S. markets of pediatrics, critical care and heart failure.
The company also reported 26% year-over-year U.S. revenue growth during the first six months of 2026, providing a broader measure of its commercial performance.
Why This Matters for Investors
The significance of the console sales extends beyond the initial equipment transactions.
Nuwellis’ business model creates an opportunity to generate additional revenue whenever hospitals use installed Aquadex systems and purchase replacement disposable blood circuits.
A larger installed base could therefore support recurring consumable sales without requiring an entirely new equipment sale for each treatment.
However, console adoption does not automatically translate into proportional recurring revenue growth.
The financial contribution depends on how frequently hospitals use the equipment, how many disposable circuits they consume and whether utilization increases over time.
The announcement establishes measurable progress in expanding the installed base but does not disclose the total number of consoles currently installed, average utilization rates or revenue generated per console.
These figures would help investors assess how effectively equipment placements are translating into recurring sales.
The combination of increased console adoption and first-half U.S. revenue growth suggests broader commercial activity across Nuwellis’ target markets.
Nevertheless, the company has not provided updated full-year revenue guidance or quantified the expected financial contribution from its 2026 console sales.
For investors, the central question is whether the expanding equipment footprint can support sustained growth in consumable revenue.
What to Watch Next
The next operational milestone will be Nuwellis’ full-year 2026 console sales total and whether it achieves one of its three highest annual placement figures.
Investors can also monitor subsequent revenue reports for evidence that the larger installed base is generating increased disposable circuit sales.
Additional disclosures on hospital utilization, consumable revenue and adoption across pediatrics, critical care and heart failure could provide greater visibility into the company’s recurring-revenue model.
Continued U.S. revenue growth will be another measure of whether the commercial progress reported in the first half of 2026 is being sustained.